conv.

← The whole story
Business
Novartis licenses BoomRay radioligand therapy asset for $900M

Deal details highlight Novartis's radioligand therapy expansion strategy

2 Yesterday · 18h ago · 1 article · 1 source · development 2 of 2

The partnership combines BoomRay's development experience in radioligand therapies with Novartis's global oncology presence. Novartis noted the deal complements its growing radioligand therapy portfolio and reflects its strategy of combining external innovation with internal research capabilities, following its 2024 acquisition of Mariana Oncology for $1 billion upfront.

Deal details highlight Novartis's radioligand therapy expansion strategy
Yahoo Finance

“Radioligand therapies represent an important frontier in oncology, and at Novartis, we remain focused on driving breakthrough science that can expand their potential for patients.”

Shiva Malek

BoomRay Pharmaceuticals Clinical-stage biotech companyNovartis Global pharmaceutical companyBo Shan BoomRay CEOShiva Malek Novartis oncology, biomedical research global head

The whole story articles the bright band is this development · numbered dots are the others · click one to jump

Peak 5 pieces in one hour at Sep 22, 12 PM; 6 pieces over 38 hours (6 articles) Sep 22, 12 PM — 5 pieces · 5 articles — Google News 5Sep 22, 1 PM — quietSep 22, 2 PM — quietSep 22, 3 PM — quietSep 22, 4 PM — quietSep 22, 5 PM — quietSep 22, 6 PM — quietSep 22, 7 PM — quietSep 22, 8 PM — quietSep 22, 9 PM — quietSep 22, 10 PM — quietSep 22, 11 PM — quietYesterday, 12 AM — quietYesterday, 1 AM — quietYesterday, 2 AM — quietYesterday, 3 AM — quietYesterday, 4 AM — quietYesterday, 5 AM — 1 piece · 1 article — Newswires 1Yesterday, 6 AM — quietYesterday, 7 AM — quietYesterday, 8 AM — quietYesterday, 9 AM — quietYesterday, 10 AM — quietYesterday, 11 AM — quietYesterday, 12 PM — quietYesterday, 1 PM — quietYesterday, 2 PM — quietYesterday, 3 PM — quietYesterday, 4 PM — quietYesterday, 5 PM — quietYesterday, 6 PM — quietYesterday, 7 PM — quietYesterday, 8 PM — quietYesterday, 9 PM — quietYesterday, 10 PM — quietYesterday, 11 PM — quietToday, 12 AM — quietToday, 1 AM — quiet 12
1Novartis and BoomRay sign $900M…2Deal details highlight Novartis's…
4 PMyesterday8 AM4 PMnow · 2:58 AM ET

Reported in the same hours no headline names this development itself — these 1 claim were published in its stretch

  1. 1 outlet BoomRay and Novartis Pharma sign $900m deal for radioligand therapy

    first by Yahoo Finance, 20h ago

All 2 developments of Novartis licenses BoomRay radioligand therapy asset for… →

Google NewsNewswires